Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes

被引:189
|
作者
Yamazaki, H [1 ]
Inoue, K [1 ]
Hashimoto, M [1 ]
Shimada, T [1 ]
机构
[1] Osaka Prefectural Inst Publ Hlth, Higashinari Ku, Osaka 537, Japan
关键词
nicotine; CYP2A6; CYP2B6; human P450; liver microsomes;
D O I
10.1007/s002040050588
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
Nicotine C-oxidation by recombinant human cytochrome P450 (P450 or CYP) enzymes and by human liver microsomes was investigated using a convenient high-performance liquid chromatographic method. Experiments with recombinant human P350 enzymes in baculovirus systems, which co-express human nicotinamide adenine dinucleotide phosphate (reduced form) (NADPH)-P450 reductase, revealed that CYP2A6 had the highest nicotine C-oxidation activities followed by CYP2B6 and CYP2D6; the K-m values by these three P450 enzymes were determined to be 11.0, 105, and 132 mu M, respectively, and the V-max values to be 11.0, 8.2, and 8.6 nmol/min per nmol P450. respectively. CYP2E1, 2C19, 1A2, 2C8, 3A4, 2C9, and 1A1 catalysed nicotine C-oxidation only at high (500 mu M) substrate concentration. CYP1B1, 2C18, 3A5, and 4A11 had no measurable activities even at 500 mu M nicotine. In liver microsomes of 16 human samples, nicotine C-oxidation activities were correlated with CYP2A6 contents at 10 mu M substrate concentration, whereas such correlation coefficients were decreased when the substrate concentration was increased to 500 mu M. Contribution of CYP2B6 (as well as CYP2A6) was demonstrated by experiments with the effects of orphenadrine (and also coumarin and anti-CYP2A6) on the nicotine C-oxidation activities by human liver microsomes at 500 CIM nicotine. CYP2D6 was found to have minor roles since quinidine did not inhibit microsomal nicotine C-oxidation at both 10 and 500 mu M substrate concentrations. These results support the view that CYP2A6 has major roles for nicotine C-oxidation at lower substrate concentration and both CYP2A6 and 2B6 play roles at higher substrate concentrations in human liver microsomes.
引用
收藏
页码:65 / 70
页数:6
相关论文
共 50 条
  • [31] Characterization of CYP2B6 and CYP2A6 Pharmacogenetic Variation in Sub-Saharan African Populations
    Twesigomwe, David
    Droegemoeller, Britt I.
    Wright, Galen E. B.
    Adebamowo, Clement
    Agongo, Godfred
    Boua, Palwende R.
    Matshaba, Mogomotsi
    Paximadis, Maria
    Ramsay, Michele
    Simo, Gustave
    Simuunza, Martin C.
    Tiemessen, Caroline T.
    Lombard, Zane
    Hazelhurst, Scott
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 (03) : 576 - 594
  • [32] CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes
    Ramírez, J
    Innocenti, F
    Schuetz, EG
    Flockhart, DA
    Relling, MV
    Santucci, R
    Ratain, MJ
    DRUG METABOLISM AND DISPOSITION, 2004, 32 (09) : 930 - 936
  • [33] Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes
    Hijazi, Y
    Boulieu, R
    DRUG METABOLISM AND DISPOSITION, 2002, 30 (07) : 853 - 858
  • [34] The role of CYP2A6*2 in nicotine metabolism
    Riexinger, A
    Collins, S
    Gaertner, I
    Farger, G
    Batra, A
    NICOTINE & TOBACCO RESEARCH, 2005, 7 (04) : 653 - 653
  • [35] Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam
    M. I. Veiga
    S. Asimus
    P. E. Ferreira
    J. P. Martins
    I. Cavaco
    V. Ribeiro
    T. N. Hai
    M. G. Petzold
    A. Björkman
    M. Ashton
    J. P. Gil
    European Journal of Clinical Pharmacology, 2009, 65 : 355 - 363
  • [36] Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam
    Veiga, M. I.
    Asimus, S.
    Ferreira, P. E.
    Martins, J. P.
    Cavaco, I.
    Ribeiro, V.
    Hai, T. N.
    Petzold, M. G.
    Bjorkman, A.
    Ashton, M.
    Gil, J. P.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 65 (04) : 355 - 363
  • [37] CYP2B6 is responsible for interindividual variability of propofol hydroxylation by human liver microsomes.
    Court, MH
    Duan, SX
    Hesse, LM
    Greenblatt, DJ
    FASEB JOURNAL, 2000, 14 (08): : A1338 - A1338
  • [38] Stereoselective Metabolism of Bupropion by Cytochrome P4502B6 (CYP2B6) and Human Liver Microsomes
    Rebecka Coles
    Evan D. Kharasch
    Pharmaceutical Research, 2008, 25 : 1405 - 1411
  • [39] Characterization of CYP2A6 involved in 3'-hydroxylation of cotinine in human liver microsomes
    Nakajima, M
    Yamamoto, T
    Nunoya, KI
    Yokoi, T
    Nagashima, K
    Inoue, K
    Funae, Y
    Shimada, N
    Kamataki, T
    Kuroiwa, Y
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1996, 277 (02): : 1010 - 1015
  • [40] Stereoselective metabolism of bupropion by cytochrome P4502B6 (CYP2B6) and human liver microsomes
    Coles, Rebeeka
    Kharasch, Evan D.
    PHARMACEUTICAL RESEARCH, 2008, 25 (06) : 1405 - 1411